Introduction: Pseudohypoparathyroidism 1A (PHP1A) is the best-known representative of inactivating PTH/PTHrP signaling disorders (iPPSD). The associated phenotype develops over time and often includes hormonal resistances, short stature and osteoma cutis. More complex and very early manifestations have also been reported. Neonatal complications may indicate a more severe course of the disease. Here we report 3 patients with heterozygous GNAS-variants and infancy-onset of iPPSD2 / PHP1A.

Case Presentations: Patient 1 is a 15-month-old boy, who presented with severe chronic noninfectious diarrhea and elevated TSH beginning at 1 month of age, leading to life-threatening failure to thrive. Patient 2 is a 4-year-old boy with a history of bronchopulmonary dysplasia as well as neonatal-onset severe pulmonary complications, including critical pulmonary bleeding and recurring pulmonary infections and TSH elevation. Patient 3 is a 4-year-old girl, who exhibited signs of PTH resistance and progressive osteoma cutis at the age of 1-2 weeks and obesity at the age of 3 months.

Conclusion: The phenotypic spectrum of iPPSD2/ PHP1A in neonates and infants may include severe gastrointestinal, pulmonary and endocrine manifestations, which may delay diagnosis if not recognized as a spectrum-disorder of Gsα deficiency. The cases support the hypothesis that early-life manifestations may indicate a more complicated course of the disease. Elevated PTH or TSH in infants with unclear symptoms or conditions should prompt evaluation for disorders of the iPPSD spectrum. In the absence of reliable predictors for the individual courses of PHP1A, in depth clinical screening for possible manifestations beyond the classical spectrum is warranted even in infancy.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000543167DOI Listing

Publication Analysis

Top Keywords

disorders ippsd
8
osteoma cutis
8
course disease
8
patient 4-year-old
8
endocrine chameleon
4
chameleon expanding
4
expanding phenotype
4
phenotype pseudohypoparathyroidism
4
pseudohypoparathyroidism infancy
4
infancy introduction
4

Similar Publications

Introduction: Pseudohypoparathyroidism 1A (PHP1A) is the best-known representative of inactivating PTH/PTHrP signaling disorders (iPPSD). The associated phenotype develops over time and often includes hormonal resistances, short stature and osteoma cutis. More complex and very early manifestations have also been reported.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates hearing loss in patients with pseudohypoparathyroidism (PHP) and related disorders, which typically show symptoms like short stature and bone abnormalities during childhood.
  • Conducted at Bicêtre Paris-Saclay Hospital, the research analyzed patient data for auditory health and established that 39% of the participants experienced hearing impairment.
  • Significant predictors of hearing loss identified were short stature and ectopic ossifications, while factors such as sex, BMI, and specific genetic mutations showed no correlation.
View Article and Find Full Text PDF

Characterization of Digestive Manifestations in Patients with Impaired PTH/PTHrP Signaling Disorder/Pseudohypoparathyroidism.

Horm Res Paediatr

August 2024

Pediatric Nutrition and Gastroenterology Department, Reference Center for Rare Disorders, PRADORT (Syndrome de PRADer-Willi et autres Obésités Rares avec Troubles du comportement alimentaire), Trousseau Hospital, AP-HP, Sorbonne University, Paris, France.

Article Synopsis
  • Pseudohypoparathyroidism is a rare condition linked to issues with the GNAS gene, leading to resistance to certain hormones and symptoms like short stature, obesity, and ossifications.
  • This study aimed to investigate the frequency of digestive problems, particularly constipation, in children with iPPSD types 2 and 3, involving 36 patients aged 2 to 18 years.
  • Results revealed that over 60% of participants reported constipation, with only a small percentage finding treatment effective, while other digestive issues like vomiting and food selectivity were also common.
View Article and Find Full Text PDF
Article Synopsis
  • Pseudohypoparathyroidism (PHP) is a rare hereditary disorder resulting in hormone resistance, with the study focusing on hypercalcitoninemia in affected patients.
  • A retrospective analysis was conducted on 88 children and 43 adults from European endocrinology centers, revealing high rates of hypercalcitoninemia (65.9% in children, 53.5% in adults) with stable calcitonin levels over time and no correlation with parathormone levels.
  • The study highlights that hypercalcitoninemia is frequently seen in PHP/iPPSD patients, particularly in specific subtypes, and suggests these patients have a distinctive response to calcium stimulation tests compared to healthy individuals and those with medullary thyroid
View Article and Find Full Text PDF

Recombinant growth hormone improves growth and adult height in patients with maternal inactivating GNAS mutations.

Eur J Endocrinol

July 2023

Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, AP-HP, Bicêtre Paris-Saclay University Hospital, 94270 Le Kremlin-Bicêtre, France.

Article Synopsis
  • Maternal inactivating GNAS mutations cause pseudohypoparathyroidism 1A (PHP1A), leading to growth issues, hormone resistance, and other physical symptoms in affected individuals.
  • A study examined the effects of recombinant human growth hormone (rhGH) on growth in 190 patients, comparing those who received treatment to untreated controls to evaluate height outcomes.
  • Results showed that rhGH significantly improved height in treated patients after 1 and 3 years, highlighting its potential benefits, but further research is needed to ensure long-term safety and effectiveness.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!